First Allied Advisory Services’s TherapeuticsMD TXMD Stock Holding History

First Allied Advisory Services’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-270	Closed	-$51K	–	1189
2018 Q4	$51K	Hold	270	–	–	﹤0.01%	1046
2018 Q3	$89K	Buy	270 +25	+10%	+$7.66K	﹤0.01%	1149
2018 Q2	$74K	Buy	+245	New	+$74.8K	﹤0.01%	1123

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

First Allied Advisory Services's TXMD Position: Q1 2019 in Review

First Allied Advisory Services sold out of TherapeuticsMD (TXMD) in Q1 2019, closing a stake of 270 shares — an estimated $51K sold.

First Allied Advisory Services first reported a position in TXMD in Q2 2018 and held it in 3 quarters. The position peaked at $89K in Q3 2018. 146 funds tracked by Wall St. Rank hold TXMD as of Q1 2019.

First Allied Advisory Services reported no remaining TherapeuticsMD position as of Q1 2019 after selling out during the quarter.
First Allied Advisory Services sold 270 TherapeuticsMD shares in Q1 2019, an estimated $51K.
First Allied Advisory Services first reported a position in TherapeuticsMD in Q2 2018 and held it in 3 quarters.
First Allied Advisory Services's TherapeuticsMD position peaked at $89K in Q3 2018.
146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2019.

Based on First Allied Advisory Services's 13F filing for Q1 2019, filed 6 May 2019.